# OnCo record nct06780111 (trial). Data CC BY-NC 4.0, attribute "Data from OnCo (onco.cc)". Whole corpus: https://onco.cc/api/v1/onco.nt
@prefix schema: <https://schema.org/> .
@prefix onco: <https://onco.cc/ns#> .
@prefix xsd: <http://www.w3.org/2001/XMLSchema#> .

<https://onco.cc/trials/nct06780111/>
  a schema:MedicalTrial ;
  onco:kind "trial" ;
  schema:identifier "nct06780111", "NCT06780111" ;
  schema:name "Substudy 06E: Umbrella Study of Combination Therapies in Esophageal Cancer (MK-3475-06E/KEYMAKER-U06)"@en ;
  schema:alternateName "KEYMAKER-U06"@en ;
  schema:description "A phase 1/2 trial of Pembrolizumab, Fluorouracil (5-FU), Oxaliplatin and Sacituzumab tirumotecan in oesophageal cancer, run by Merck Sharp & Dohme LLC, now recruiting."@en ;
  schema:url <https://onco.cc/trials/nct06780111/> ;
  schema:dateModified "2026-09-16"^^xsd:date ;
  schema:citation <https://clinicaltrials.gov/study/NCT06780111> ;
  onco:status "recruiting" ;
  onco:tag "pipeline", "ctgov-ingest" ;
  onco:phase "1/2" ;
  schema:startDate "2025-07-30" ;
  onco:cancers <https://onco.cc/cancers/esophageal/> ;
  onco:technologies <https://onco.cc/technologies/checkpoint-inhibitor/> ;
  onco:drugs <https://onco.cc/drugs/pembrolizumab/>, <https://onco.cc/drugs/fluorouracil/>, <https://onco.cc/drugs/oxaliplatin/>, <https://onco.cc/drugs/sacituzumab-tirumotecan/> ;
  onco:companies <https://onco.cc/companies/merck/>, <https://onco.cc/companies/daiichi-sankyo/> .